Vividion Therapeutics racks up $135m Series C

Vividion Therapeutics, Inc., a biotechnology company, has secured $135 million in Series C financing.

Vividion Therapeutics, Inc., a biotechnology company, has secured $135 million in Series C financing. Logos Capital and Boxer Capital of Tavistock Group led the round.

Source: Press Release